This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wednesday's Health Winners & Losers

Health stocks looked vibrant Wednesday after a plethora of regulatory and clinical updates.

First, a Food and Drug Administration advisory panel on Tuesday voted against the setting targets that would have further restricted the use of Amgen's (AMGN - Get Report) anemia drug Epogen and Johnson & Johnson's (JNJ - Get Report) Procrit in dialysis and predialysis patients, instead opting for a range to guide the use of the drugs in those patients. Amgen shares were up $2.02, or 3.8%, to $55.94 Wednesday.

A smaller-cap company, Vision-Sciences (VSCI), took off Wednesday after announcing that it received 510(k) clearance from the FDA to market a new line of digital, video-based flexible endoscopes, which come with an integrated "built-in" light source so that a separate camera head, light cable and optical coupler aren't needed.

The ENT (ear, nose and throat) and TNE (transnasal esophagoscopy) scopes are the first two in a series to be introduced by Vision-Sciences. Shares rose 48 cents, or 26%, to $2.26.

And for the second time in two weeks, investors fueled Cardica (CRDC - Get Report) shares. The company said Wednesday that it received European CE Mark approval for its C-Port Flex A Anastomosis System, which attaches blood vessels and grafts in less-invasive coronary artery bypass graft (CABG) procedures. Cardica added $1.28, or 14.9%, to $9.93.

In the clinical update arena, biopharmaceutical company Novavax (NVAX - Get Report) said that several candidates have emerged from an ongoing discovery program to create a novel vaccine to prevent disease associated with the varicella zoster virus (VZV) in older adults, and that the candidates are now targeted for preclinical development. Shares climbed 31 cents, or 9.2%, to $3.72.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
VSCI $1.55 -5.49%
CTIC $1.71 0.00%
AMGN $163.58 0.00%
CRDC $0.43 0.00%
JNJ $101.35 0.00%


DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs